Research programme: ICOS-CD28 dual agonists - Alpine Immune Sciences

Drug Profile

Research programme: ICOS-CD28 dual agonists - Alpine Immune Sciences

Alternative Names: dual ICOS/CD28 agonist; ICOSL vIgD; V-mAb localised ICOS/CD28 agonist; V-mAbs; vIgD localised ICOS/CD28 agonist

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alpine Immune Sciences
  • Class Immunotherapies; Monoclonal antibodies; Proteins
  • Mechanism of Action CD28 antigen stimulants; Inducible T-cell co-stimulator protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Dec 2017 Pharmacodynamics data from a preclinical trial in Cancer released by Alpine Immune Sciences
  • 02 May 2017 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top